Aspergillus spp. are increasingly recognized as major fungal pathogens in immunocompromised or neutropenic patients, and Aspergillus fumigatus is responsible for nearly 90% of cases of invasive pulmonary aspergillosis (IPA) (7). As the incidence of AIDS, aplastic anemia, and organ transplantation increases and the use of chronic glucocorticoid treatment and aggressive antineoplastic chemotherapy regimes becomes more frequent, the number of patients susceptible to Aspergillus infection is rising. In immunocompromised or neutropenic patients, IPA, the most common form of the disease, is characterized by hyphal invasion and destruction of pulmonary tissue. Dissemination of Aspergillus infection to other organs occurs in approximately 20% of IPA cases (4). In spite of correct diagnosis and treatment, IPA results in patient mortality of greater than 80%. The mortality rate among bone marrow transplantation patients can be as high as 95% (26). Early empirical treatment with antifungal drugs, such as amphotericin B (AmB), reduces the mortality rate. However, AmB is considered highly nephrotoxic (18) and has often been found inadequate for complete elimination of the infection in the immunosuppressed subjects. Because invasive aspergillosis is extremely rare in immunocompetent individuals, therapy aimed at strengthening the host's immune response to the organisms offers a promising new approach in the treatment of this disease.Host defense against Aspergillus infections is considered to be mediated by macrophages, neutrophils, and polymorphonuclear cells (PMNs) (6,16,23,24,25,28). The respiratory tract appears to be the portal of entry in most cases of IPA (3). Therefore, there has been an extensive search for molecules in the lung which can selectively enhance the contribution of the innate immune mechanism of phagocytes against Aspergillus infection. Lung surfactant proteins SP-A and SP-D have potent chemotactic activity for various subsets of mononuclear leukocytes and have been shown to enhance phagocytosis and production of superoxide anion by macrophages and neutrophils (29). SP-A and SP-D, which belong to a family of proteins called collectins, are also known to interact with carbohydrate structures present on the surfaces of a wide range of pathogens, such as viruses, bacteria, and fungi, via their carbohydrate recognition domains (CRDs) and to enhance phagocytosis and killing by neutrophils and macrophages (22,29). Collectins are composed of subunits, each of which contains a collagen-like triple-helical region, followed by an ␣-helical, trimerizing neck region and three CRDs at its C-terminal end. Six of these trimeric subunits make up the overall structure of SP-A, while SP-D is composed of a cruciform structure with four arms of equal lengths (10). Mice deficient in SP-A were observed to be less effective in clearing Staphylococcus aureus and Pseudomonas aeruginosa and were more susceptible to lung inflammation and splenic dissemination of group B streptococci (13-15).We have previously shown that SP-A and S...